Solid BiosciencesSLDB
SLDB
About: Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Employees: 88
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
2,279% more call options, than puts
Call options by funds: $2.38M | Put options by funds: $100K
75% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 20
1.97% less ownership
Funds ownership: 92.89% [Q3] → 90.92% (-1.97%) [Q4]
3% less funds holding
Funds holding: 92 [Q3] → 89 (-3) [Q4]
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
42% less capital invested
Capital invested by funds: $250M [Q3] → $145M (-$105M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
160%
upside
Avg. target
$15.80
173%
upside
High target
$16
177%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Geulah Livshits 14% 1-year accuracy 7 / 51 met price target | 177%upside $16 | Buy Maintained | 19 Feb 2025 |
HC Wainwright & Co. Arthur He 16% 1-year accuracy 5 / 31 met price target | 177%upside $16 | Buy Reiterated | 13 Jan 2025 |
Truist Securities Joon Lee 58% 1-year accuracy 26 / 45 met price target | 177%upside $16 | Buy Initiated | 8 Jan 2025 |
Wedbush Laura Chico 26% 1-year accuracy 15 / 57 met price target | 177%upside $16 | Outperform Initiated | 13 Dec 2024 |
JMP Securities Silvan Tuerkcan 32% 1-year accuracy 18 / 56 met price target | 160%upside $15 | Market Outperform Initiated | 10 Dec 2024 |
Financial journalist opinion
Based on 4 articles about SLDB published over the past 30 days
Positive
MarketBeat
2 days ago
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Shares of biotech company Solid Biosciences NASDAQ: SLDB skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%.
Positive
Benzinga
3 days ago
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
On Tuesday, Solid Biosciences Inc. SLDB released initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy.
Neutral
GlobeNewsWire
4 days ago
Solid Biosciences Announces Pricing of Underwritten Offering
CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 13,888,340 shares of common stock at an offering price of $4.029 per pre-funded warrant. The aggregate gross proceeds of the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. All of the securities in the offering are being sold by Solid. The offering is expected to close on or about February 19, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
4 days ago
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
— Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February 11, 2025, with no serious adverse events observed —— Participant enrollment continues, with the 7th participant dosed on February 17, 2025; Company expects to dose approximately 20 total participants by Q4 2025 —— In mid-2025, Company plans to request an FDA meeting to discuss potential accelerated approval pathway for SGT-003 —— Company to hold a conference call today at 8:00 AM ET —
Positive
Seeking Alpha
1 month ago
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to $7.56 billion in 2034. Data from the first 3 patients of the phase 1/2 INSPIRE DUCHENNE study, using SGT-003 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q1 of 2025.
Neutral
GlobeNewsWire
1 month ago
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia
- Only dual route gene transfer therapy in development to treat Friedreich's ataxia with FDA IND clearance and Fast Track designation -
Neutral
GlobeNewsWire
1 month ago
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
- Duchenne : Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -
Neutral
GlobeNewsWire
1 month ago
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
Positive
Zacks Investment Research
1 month ago
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia.
Neutral
GlobeNewsWire
1 month ago
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia -
Charts implemented using Lightweight Charts™